Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Cerevel Therapeutics files to sell 76.78M shares of common stock for holders  08:17
05/10/22
05/10
08:17
05/10/22
08:17
CERE

Cerevel Therapeutics

$22.20 /

-3.41 (-13.32%)

 
ShowHide Related Items >><<
CERE Cerevel Therapeutics
$22.20 /

-3.41 (-13.32%)

CERE Cerevel Therapeutics
$22.20 /

-3.41 (-13.32%)

02/14/22 Goldman Sachs
Cerevel Therapeutics initiated with a Neutral at Goldman Sachs
01/05/22 JPMorgan
Cerevel Therapeutics initiated with an Overweight at JPMorgan
12/16/21 H.C. Wainwright
Cerevel Therapeutics initiated with a Buy at H.C. Wainwright
11/10/21 Stifel
Cerevel Therapeutics price target raised to $50 from $33 at Stifel
CERE Cerevel Therapeutics
$22.20 /

-3.41 (-13.32%)

  • 02
    Jul
CERE Cerevel Therapeutics
$22.20 /

-3.41 (-13.32%)

Earnings
Cerevel Therapeutics reports Q1 EPS (46c), consensus (42c) » 06:46
05/10/22
05/10
06:46
05/10/22
06:46
CERE

Cerevel Therapeutics

$22.20 /

-3.41 (-13.32%)

Cash, cash equivalents…

Cash, cash equivalents and marketable securities as of March 31, 2022, were $550.9M. This cash position does not include the additional $37.5M received in April from the tavapadon risk-sharing arrangement. The Company's cash, cash equivalents and marketable securities are expected to continue to support operations into 2024. "Cerevel remains in an enviable position of strength as we seek to transform what is possible in neuroscience," said Tony Coles, chairperson and CEO of Cerevel Therapeutics. "We bring together the highest standard of clinical trial execution with the pipeline, the people, and the capital necessary to deliver new solutions for people living with vexing neuroscience diseases."

ShowHide Related Items >><<
CERE Cerevel Therapeutics
$22.20 /

-3.41 (-13.32%)

CERE Cerevel Therapeutics
$22.20 /

-3.41 (-13.32%)

02/14/22 Goldman Sachs
Cerevel Therapeutics initiated with a Neutral at Goldman Sachs
01/05/22 JPMorgan
Cerevel Therapeutics initiated with an Overweight at JPMorgan
12/16/21 H.C. Wainwright
Cerevel Therapeutics initiated with a Buy at H.C. Wainwright
11/10/21 Stifel
Cerevel Therapeutics price target raised to $50 from $33 at Stifel
CERE Cerevel Therapeutics
$22.20 /

-3.41 (-13.32%)

  • 02
    Jul
CERE Cerevel Therapeutics
$22.20 /

-3.41 (-13.32%)

Over a month ago
On The Fly
Fly Insider: Sonic Automotive, Moderna among week's notable insider trades » 15:40
04/18/22
04/18
15:40
04/18/22
15:40
CMPO

CompoSecure

$7.70 /

+0.52 (+7.24%)

, PRTY

Party City

$3.63 /

-0.2 (-5.23%)

, SAH

Sonic Automotive

$43.85 /

+0.53 (+1.22%)

, OCX

OncoCyte

$1.21 /

-0.05 (-3.97%)

, CERE

Cerevel Therapeutics

$31.90 /

-0.59 (-1.82%)

, ETSY

Etsy

$109.01 /

-6.68 (-5.77%)

, HUBS

HubSpot

$428.53 /

-17.72 (-3.97%)

, MRNA

Moderna

$156.20 /

-9.43 (-5.69%)

Welcome to "Fly Insider,"…

ShowHide Related Items >><<
SAH Sonic Automotive
$43.85 /

+0.53 (+1.22%)

PRTY Party City
$3.63 /

-0.2 (-5.23%)

OCX OncoCyte
$1.21 /

-0.05 (-3.97%)

MRNA Moderna
$156.20 /

-9.43 (-5.69%)

HUBS HubSpot
$428.53 /

-17.72 (-3.97%)

ETSY Etsy
$109.01 /

-6.68 (-5.77%)

CERE Cerevel Therapeutics
$31.90 /

-0.59 (-1.82%)

CMPO CompoSecure
$7.70 /

+0.52 (+7.24%)

01/28/22 Needham
CompoSecure initiated with a Buy at Needham
01/07/22 B. Riley
CompoSecure initiated with a Buy at B. Riley
PRTY Party City
$3.63 /

-0.2 (-5.23%)

SAH Sonic Automotive
$43.85 /

+0.53 (+1.22%)

04/07/22 JPMorgan
Sonic Automotive downgraded to Neutral from Overweight at JPMorgan
11/17/21 Morgan Stanley
Penske Automotive downgraded to Underweight at Morgan Stanley
11/17/21 Morgan Stanley
Sonic Automotive downgraded to Underweight at Morgan Stanley
11/17/21 Morgan Stanley
Sonic Automotive downgraded to Underweight from Equal Weight at Morgan Stanley
OCX OncoCyte
$1.21 /

-0.05 (-3.97%)

03/17/22 Piper Sandler
OncoCyte price target lowered to $1.80 from $3.10 at Piper Sandler
03/14/22 KeyBanc
KeyBanc downgrades OncoCyte to Sector Weight
03/14/22 KeyBanc
OncoCyte downgraded to Sector Weight from Overweight at KeyBanc
03/11/22 Lake Street
OncoCyte price target lowered to $6 from $11 at Lake Street
CERE Cerevel Therapeutics
$31.90 /

-0.59 (-1.82%)

02/14/22 Goldman Sachs
Cerevel Therapeutics initiated with a Neutral at Goldman Sachs
01/05/22 JPMorgan
Cerevel Therapeutics initiated with an Overweight at JPMorgan
12/16/21 H.C. Wainwright
Cerevel Therapeutics initiated with a Buy at H.C. Wainwright
11/10/21 Stifel
Cerevel Therapeutics price target raised to $50 from $33 at Stifel
ETSY Etsy
$109.01 /

-6.68 (-5.77%)

04/13/22 Oppenheimer
Etsy price target lowered to $175 from $215 at Oppenheimer
03/31/22 Stifel
Poshmark downgraded to Hold from Buy at Stifel
03/29/22 Loop Capital
Etsy downgraded to Hold from Buy at Loop Capital
03/29/22 Loop Capital
Etsy downgraded to Hold from Buy at Loop Capital
HUBS HubSpot
$428.53 /

-17.72 (-3.97%)

03/21/22 Stifel
HubSpot price target lowered to $700 from $850 at Stifel
03/15/22 Wells Fargo
HubSpot price target lowered to $675 from $725 at Wells Fargo
02/14/22 Canaccord
HubSpot price target lowered to $675 from $845 at Canaccord
02/11/22 Truist
HubSpot price target lowered to $700 from $900 at Truist
MRNA Moderna
$156.20 /

-9.43 (-5.69%)

04/11/22 Piper Sandler
CFO leaves Dentsply for Moderna, outside replacement more likely, says Piper
03/25/22 Piper Sandler
Moderna pipeline growing and 'de-risked,' says Piper Sandler
03/23/22 Piper Sandler
Moderna's Phase II/III KidCOVE trial meets endpoints, says Piper Sandler
03/10/22 Piper Sandler
Moderna's Vaccine Day to highlight expanding pipeline, says Piper Sandler
SAH Sonic Automotive
$43.85 /

+0.53 (+1.22%)

PRTY Party City
$3.63 /

-0.2 (-5.23%)

OCX OncoCyte
$1.21 /

-0.05 (-3.97%)

MRNA Moderna
$156.20 /

-9.43 (-5.69%)

HUBS HubSpot
$428.53 /

-17.72 (-3.97%)

ETSY Etsy
$109.01 /

-6.68 (-5.77%)

CMPO CompoSecure
$7.70 /

+0.52 (+7.24%)

CERE Cerevel Therapeutics
$31.90 /

-0.59 (-1.82%)

  • 14
    Apr
  • 02
    Jul
MRNA Moderna
$156.20 /

-9.43 (-5.69%)

HUBS HubSpot
$428.53 /

-17.72 (-3.97%)

ETSY Etsy
$109.01 /

-6.68 (-5.77%)

PRTY Party City
$3.63 /

-0.2 (-5.23%)

OCX OncoCyte
$1.21 /

-0.05 (-3.97%)

MRNA Moderna
$156.20 /

-9.43 (-5.69%)

HUBS HubSpot
$428.53 /

-17.72 (-3.97%)

ETSY Etsy
$109.01 /

-6.68 (-5.77%)

CMPO CompoSecure
$7.70 /

+0.52 (+7.24%)

PRTY Party City
$3.63 /

-0.2 (-5.23%)

MRNA Moderna
$156.20 /

-9.43 (-5.69%)

ETSY Etsy
$109.01 /

-6.68 (-5.77%)

Conference/Events
Cerevel Therapeutics management to meet virtually with Jefferies » 12:55
03/23/22
03/23
12:55
03/23/22
12:55
CERE

Cerevel Therapeutics

$33.70 /

+0.44 (+1.32%)

Biotechnology Analyst Yee…

Biotechnology Analyst Yee holds a Virtual Meeting with CEO Coles, Chief Scientific Officer Rengerand and Chief Medical Officer Sanchez on March 23 at 1 pm. hosted by Jefferies.

ShowHide Related Items >><<
CERE Cerevel Therapeutics
$33.70 /

+0.44 (+1.32%)

CERE Cerevel Therapeutics
$33.70 /

+0.44 (+1.32%)

02/14/22 Goldman Sachs
Cerevel Therapeutics initiated with a Neutral at Goldman Sachs
01/05/22 JPMorgan
Cerevel Therapeutics initiated with an Overweight at JPMorgan
12/16/21 H.C. Wainwright
Cerevel Therapeutics initiated with a Buy at H.C. Wainwright
11/10/21 Stifel
Cerevel Therapeutics price target raised to $50 from $33 at Stifel
CERE Cerevel Therapeutics
$33.70 /

+0.44 (+1.32%)

  • 02
    Jul
Conference/Events
Cerevel Therapeutics management to meet virtually with Jefferies » 10:16
03/23/22
03/23
10:16
03/23/22
10:16
CERE

Cerevel Therapeutics

$32.70 /

-0.56 (-1.68%)

Biotechnology Analyst Yee…

Biotechnology Analyst Yee holds a Virtual Meeting with CEO Coles, Chief Scientific Officer Rengerand and Chief Medical Officer Sanchez on March 23 at 1 pm. hosted by Jefferies.

ShowHide Related Items >><<
CERE Cerevel Therapeutics
$32.70 /

-0.56 (-1.68%)

CERE Cerevel Therapeutics
$32.70 /

-0.56 (-1.68%)

02/14/22 Goldman Sachs
Cerevel Therapeutics initiated with a Neutral at Goldman Sachs
01/05/22 JPMorgan
Cerevel Therapeutics initiated with an Overweight at JPMorgan
12/16/21 H.C. Wainwright
Cerevel Therapeutics initiated with a Buy at H.C. Wainwright
11/10/21 Stifel
Cerevel Therapeutics price target raised to $50 from $33 at Stifel
CERE Cerevel Therapeutics
$32.70 /

-0.56 (-1.68%)

  • 02
    Jul
Earnings
Cerevel Therapeutics reports Q4 EPS (40c), consensus (41c) » 06:34
03/01/22
03/01
06:34
03/01/22
06:34
CERE

Cerevel Therapeutics

$26.44 /

+1.05 (+4.14%)

The company anticipates…

The company anticipates R&D expenses for 2022 to increase relative to 2021, driven by initiation of the comprehensive Phase 2 program for emraclidine; increased costs associated with advancement of the Phase 3 program for tavapadon; continued investment in darigabat, CVL-871 and early discovery efforts; and higher personnel costs to support the growth and advancement of its pipeline. Cerevel expects G&A expenses for 2022 to increase relative to 2021 to support the expansion and advancement of its pipeline and initiate pre-commercialization activities. The company's cash, cash equivalents and marketable securities are expected to continue to support operations into 2024.

ShowHide Related Items >><<
CERE Cerevel Therapeutics
$26.44 /

+1.05 (+4.14%)

CERE Cerevel Therapeutics
$26.44 /

+1.05 (+4.14%)

02/14/22 Goldman Sachs
Cerevel Therapeutics initiated with a Neutral at Goldman Sachs
01/05/22 JPMorgan
Cerevel Therapeutics initiated with an Overweight at JPMorgan
12/16/21 H.C. Wainwright
Cerevel Therapeutics initiated with a Buy at H.C. Wainwright
11/10/21 Stifel
Cerevel Therapeutics price target raised to $50 from $33 at Stifel
CERE Cerevel Therapeutics
$26.44 /

+1.05 (+4.14%)

  • 02
    Jul
Over a quarter ago
Hot Stocks
Cerevel Therapeutics announces results from Phase 1 trial evaluating darigabat » 06:36
02/15/22
02/15
06:36
02/15/22
06:36
CERE

Cerevel Therapeutics

$31.10 /

+0.5 (+1.63%)

Cerevel Therapeutics…

Cerevel Therapeutics announced positive results from its Phase 1 healthy volunteer clinical trial to evaluate darigabat, a novel alpha-2/3/5 selective GABAA receptor positive allosteric modulator, or PAM, in acute anxiety. Both the 7.5 mg twice-daily and the 25 mg twice-daily doses of darigabat demonstrated clinically meaningful and statistically significant anxiolytic activity compared with placebo in this proof-of-principle trial. The positive control alprazolam 1 mg twice-daily exhibited placebo-adjusted anxiolytic activity in line with expectations for this trial design. After eight days of treatment, the darigabat 7.5 mg and 25 mg twice-daily doses demonstrated a 3.9 point and 4.5 point placebo-adjusted improvement, respectively, on the primary endpoint of the Panic Symptoms List (PSL-IV) total score. The alprazolam 1 mg twice-daily dose demonstrated a 1.6 point placebo-adjusted improvement on the PSL-IV total score. These positive results were further supported by the secondary endpoint, change in the Fear Visual Analog Scale, which demonstrated a 12.8 point, 7.8 point, and 0.9 point placebo-adjusted improvement for the darigabat 7.5 mg, 25 mg, and alprazolam 1 mg twice-daily doses, respectively.

ShowHide Related Items >><<
CERE Cerevel Therapeutics
$31.10 /

+0.5 (+1.63%)

CERE Cerevel Therapeutics
$31.10 /

+0.5 (+1.63%)

02/14/22 Goldman Sachs
Cerevel Therapeutics initiated with a Neutral at Goldman Sachs
01/05/22 JPMorgan
Cerevel Therapeutics initiated with an Overweight at JPMorgan
12/16/21 H.C. Wainwright
Cerevel Therapeutics initiated with a Buy at H.C. Wainwright
11/10/21 Stifel
Cerevel Therapeutics price target raised to $50 from $33 at Stifel
CERE Cerevel Therapeutics
$31.10 /

+0.5 (+1.63%)

  • 02
    Jul
Initiation
Cerevel Therapeutics initiated with a Neutral at Goldman Sachs » 16:23
02/14/22
02/14
16:23
02/14/22
16:23
CERE

Cerevel Therapeutics

$31.10 /

+0.5 (+1.63%)

Goldman Sachs analyst…

Goldman Sachs analyst Madhu Kumar initiated coverage of Cerevel Therapeutics with a Neutral rating and $27 price target. The late clinical-stage CNS therapeutics company's lead asset is tavapadon, which has top-line data from a Phase 3 TEMPO-3 trial expected in the first half of 2023 and top-line data from the Phase 3 TEMPO-1/2 trials due in the second half of next year. While Kumar has "enthusiasm" for several of Cerevel's CNS pipeline prospects, he views the current risk-reward as balanced, the analyst said.

ShowHide Related Items >><<
CERE Cerevel Therapeutics
$31.10 /

+0.5 (+1.63%)

CERE Cerevel Therapeutics
$31.10 /

+0.5 (+1.63%)

01/05/22 JPMorgan
Cerevel Therapeutics initiated with an Overweight at JPMorgan
12/16/21 H.C. Wainwright
Cerevel Therapeutics initiated with a Buy at H.C. Wainwright
11/10/21 Stifel
Cerevel Therapeutics price target raised to $50 from $33 at Stifel
10/08/21 Jefferies
Cerevel Therapeutics price target raised to $37 from $30 at Jefferies
CERE Cerevel Therapeutics
$31.10 /

+0.5 (+1.63%)

  • 02
    Jul
Conference/Events
Cerevel Therapeutics participates in a conference call with Stifel » 13:25
01/25/22
01/25
13:25
01/25/22
13:25
CERE

Cerevel Therapeutics

$25.00 /

-1.26 (-4.80%)

Biotech Analyst Matteis…

Biotech Analyst Matteis holds a conference call with management on January 25 at 2 pm hosted by Stifel.

ShowHide Related Items >><<
CERE Cerevel Therapeutics
$25.00 /

-1.26 (-4.80%)

CERE Cerevel Therapeutics
$25.00 /

-1.26 (-4.80%)

01/05/22 JPMorgan
Cerevel Therapeutics initiated with an Overweight at JPMorgan
12/16/21 H.C. Wainwright
Cerevel Therapeutics initiated with a Buy at H.C. Wainwright
11/10/21 Stifel
Cerevel Therapeutics price target raised to $50 from $33 at Stifel
10/08/21 Jefferies
Cerevel Therapeutics price target raised to $37 from $30 at Jefferies
CERE Cerevel Therapeutics
$25.00 /

-1.26 (-4.80%)

  • 02
    Jul
Conference/Events
Cerevel Therapeutics participates in a conference call with Stifel » 10:22
01/25/22
01/25
10:22
01/25/22
10:22
CERE

Cerevel Therapeutics

$25.06 /

-1.2 (-4.57%)

Biotech Analyst Matteis…

Biotech Analyst Matteis holds a conference call with management on January 25 at 2 pm hosted by Stifel.

ShowHide Related Items >><<
CERE Cerevel Therapeutics
$25.06 /

-1.2 (-4.57%)

CERE Cerevel Therapeutics
$25.06 /

-1.2 (-4.57%)

01/05/22 JPMorgan
Cerevel Therapeutics initiated with an Overweight at JPMorgan
12/16/21 H.C. Wainwright
Cerevel Therapeutics initiated with a Buy at H.C. Wainwright
11/10/21 Stifel
Cerevel Therapeutics price target raised to $50 from $33 at Stifel
10/08/21 Jefferies
Cerevel Therapeutics price target raised to $37 from $30 at Jefferies
CERE Cerevel Therapeutics
$25.06 /

-1.2 (-4.57%)

  • 02
    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.